RxDoctor Payments Data

Mohamed Dahhan, MD

Internal Medicine · Paterson, NJNPI 1417279779

Payments from drug & device makers

$9,119in general payments, 2019–2025

Across 190 payments — averaging $47.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Madrigal Pharmaceuticals$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$877
  • Bayer$705
  • Amgen$663
  • Novo Nordisk$525
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$9,112100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,119 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$40,800
Medicare patients
141
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$69,583
OzempicSemaglutide70$66,480
JanumetSitagliptin Phos/Metformin Hcl62$48,887
JanuviaSitagliptin Phosphate51$48,013
FarxigaDapagliflozin Propanediol59$45,833
Icosapent Ethyl66$32,306
VascepaIcosapent Ethyl71$31,281
KerendiaFinerenone39$27,817
LinzessLinaclotide35$25,268
Lactulose16$23,818
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate23$22,200
TrulicityDulaglutide11$19,473
Diclofenac Sodium219$15,785
Dihydroergotamine Mesylate12$11,134
TradjentaLinagliptin13$10,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia$12$96,900113 claims
Novo NordiskOzempic$525$66,48070 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,735$57,15882 claims
BayerKerendia$705$27,81739 claims
AbbVieLinzess$373$25,26835 claims
Lilly USA, LLCTrulicity$30$19,47311 claims
GSKBreo Ellipta, Incruse Ellipta$292$16,27435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →